Molecular and Cellular Mechanisms Underlying the Antidepressant Effects of Ketamine Enantiomers and Its Metabolites

Chun Yang,Jianjun Yang,Ailin Luo,Kenji Hashimoto

DOI: https://doi.org/10.1038/s41398-019-0624-1

2019-01-01

Translational Psychiatry

Abstract:Although the robust antidepressant effects of the N -methyl- d -aspartate receptor (NMDAR) antagonist ketamine in patients with treatment-resistant depression are beyond doubt, the precise molecular and cellular mechanisms underlying its antidepressant effects remain unknown. NMDAR inhibition and the subsequent α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) activation are suggested to play a role in the antidepressant effects of ketamine. Although ( R )-ketamine is a less potent NMDAR antagonist than ( S )-ketamine, ( R )-ketamine has shown more marked and longer-lasting antidepressant-like effects than ( S )-ketamine in several animal models of depression. Furthermore, non-ketamine NMDAR antagonists do not exhibit robust ketamine-like antidepressant effects in patients with depression. These findings suggest that mechanisms other than NMDAR inhibition play a key role in the antidepressant effects of ketamine. Duman’s group demonstrated that the activation of mammalian target of rapamycin complex 1 (mTORC1) in the medial prefrontal cortex is reportedly involved in the antidepressant effects of ketamine. However, we reported that mTORC1 serves a role in the antidepressant effects of ( S )-ketamine, but not of ( R )-ketamine, and that extracellular signal-regulated kinase possibly underlie the antidepressant effects of ( R )-ketamine. Several lines of evidence have demonstrated that brain-derived neurotrophic factor (BDNF) and its receptor, tyrosine kinase receptor B (TrkB), are crucial in the antidepressant effects of ketamine and its two enantiomers, ( R )-ketamine and ( S )-ketamine, in rodents. In addition, (2 R ,6 R )-hydroxynormetamine [a metabolite of ( R )-ketamine] and ( S )-norketamine [a metabolite of ( S )-ketamine] have been shown to exhibit antidepressant-like effects on rodents through the BDNF–TrkB cascade. In this review, we discuss recent findings on the molecular and cellular mechanisms underlying the antidepressant effects of enantiomers of ketamine and its metabolites. It may be time to reconsider the hypothesis of NMDAR inhibition and the subsequent AMPAR activation in the antidepressant effects of ketamine.